Angers

• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting
  2023-507778-42-00 4 2023-03-08 Non-Small Cell Lung Cancer II, III
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 4 2023-01-25 ER positive HER2 negative breast cancer
• Effectiveness of an Optimisation Strategy for Emergency Tracheal Intubation on postintubation Morbidity: A superiority cluster randomised co … Recruiting
  2024-514913-37-00 11 2023-01-12 Respiratory distress
• A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses o … Recruiting
  2024-514328-18-00 7 2022-12-06 Spinocerebellar ataxia types 1, 3 and Huntington's disease
• TERTIO : Evaluation de l’intérêt de combiner un vaccin inducteur de CD4-Th1 dérivé de la télomérase avec un traitement par atezolizumab et b … Recruiting
  2022-500643-20-00 4 2022-09-27 Patients with locally advanced, metastatic or unresectable hepatocellu
• Combination lock01 - Impact of aminoglycosides-based antibiotics combination and protective isolation on outcomes in critically-ill neutrope … Recruiting
  2024-514042-36-00 5 2022-09-21 Adult patients admitted to intensive care
• ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care Recruiting
  2024-513327-16-00 5 2022-09-20 Intensive care
• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 4 2022-09-15 Acute Myeloid Leukemia
• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple M … Recruiting
  2023-506247-42-00 3 2022-08-17 Relapsed/Refractory Multiple Myeloma
• Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma … Recruiting
  2024-513986-38-00 4 2022-06-01 Locally advanced or metastatic papillary cell carcinoma (PRCC)
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 9 2022-05-18 Low risk myelodysplastic syndrom without RS having failed or being ine
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl … Recruiting
  2023-506891-28-00 5 2022-05-02 The target population of interest in this study is participants with l
• Fecal Microbiota Transplantation in the prevention of complications after allogeneic hematopoietic stem cell transplantation for hematologic … Recruiting
  2024-512969-14-01 4 2022-05-02 Patient who underwent Allogeneic hematopoietic stem cell transplantati
• A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte … Recruiting
  2024-515945-40-00 10 2022-05-02 Non small cell lung cancer
• Study evaluating the tailored management of locally-advanced rectal carcinoma Recruiting
  2024-511609-44-00 10 2022-02-03 Rectum cancer
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• A Study with ABBV-CLS-484 Alone and in Combination in Subjects with Advanced Tumor Cancer Recruiting
  2023-507568-38-00 1 2022-01-14 Metastatic or locally advanced tumors
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on inci … Recruiting
  2024-515075-36-00 6 2021-12-01 kidney transplantion -Epstein Barr virus
• Predictive Signature of Benralizumab Response. BENRAPRED Study. Recruiting
  2024-514843-27-00 6 2021-10-11 Severe asthma
• Oxytocin versus Prostaglandins for labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening: a multicenter no … Recruiting
  2024-517675-20-00 11 2021-09-28 Labor Induction of women with an unfavorable Cervix after 24 hours of
• Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ov … Recruiting
  2024-515310-40-01 4 2021-08-04 Patients with a confirmed diagnosis of ovarian small cell carcinoma.

Showing 289–312 of 611 trials